Cancer Tissue Diagnostics Market

New Wave of Innovation in the Cancer Tissue Diagnostics Market: An Analysis by FMI

Cancer Tissue Diagnostics Market by Test Type & region - Forecast 2022 - 2032

Cancer Tissue Diagnostics Market Outlook (2022-2032)

[324 Pages Report] The global cancer tissue diagnostics market is expected to reach a market valuation of US$ 5.3 Billion by the year 2022, accelerating with a moderate CAGR of 6.6% by 2022-2032. Cancer tissue diagnostics market size is anticipated to be valued at about US$ 10.04 Billion by 2032 end.

The biological context of cancer cells may be captured by tissue diagnostics, making them one of the most reliable methods for making a cancer diagnosis and treatment plan. High demand and promising future growth in the cancer tissue diagnostics market might be attributed to the rising cancer rate.

Increased adoption of automated cancer diagnosis methods and technologies by research institutes facilitates quicker tumor diagnosis. The West Clinic Cancer Center, for instance, teamed with F. Hoffmann-La Roche Ltd. in September 2019 to use the BenchMark ULTRA Automated Advanced Staining System, developed by Roche, to enhance patient cancer treatment. In situ hybridization and immunohistochemistry testing can be performed using this technology for a quicker cancer tissue diagnostics.

Several factors, including the rising incidence of cancers of all kinds, the growing interest in preventative health care, the expansion of digital pathology's applications, the intensification of cancer awareness campaigns, the development of more effective diagnostic and monitoring tools, and the general improvement in diagnostic accuracy, bode well for the global cancer tissue diagnostics market.

While the global cancer tissue diagnostics market is expected to expand during the forecast period, its expansion is expected to be stymied by factors such as the high price of diagnostic procedures and a lack of experienced and professional workers in the industry.

Attributes	Value
Cancer Tissue Diagnostics Market Size (2022)	US$ 5.3 Billion
Cancer Tissue Diagnostics Market Projected Size (2032)	US$ 10.04 Billion
Cancer Tissue Diagnostics Market Value CAGR (2022-2032)	6.6%

Customize this Report

Let us know your requirement to get
100% FREE customization

Customize Now

What are Some Factors Shaping the future of Cancer Tissue Diagnostics Market?

Cancer diagnostics research is expected to drive the demand.

The rise in cancer incidence has boosted cancer tissue diagnostics research and development. According to the WHO, the global cancer burden grew in 2020, with 18 million new cases and 9.6 million deaths (WHO). Increased academic-commercial partnerships to further cancer research is likely to increase the global cancer tissue diagnostics market.

The University of Sheffield in the UK signed a collaboration agreement with Zilico Ltd in June 2020 to develop a painless, fast, and non-invasive method of diagnosing oral cancer using EIS technology.

Swiss life-sciences firm Lunaphore Technologies SA develops next-generation cancer research equipment. In the same month, Epredia, a global leader in cancer diagnostics and tissue diagnostics, signed a strategic distribution deal with the firm. Fast Fluidic Exchange microfluidic technology is forecasted to be integrated into tissue diagnostic instruments by industry leader Lunaphore to deliver chemicals to tissue samples for quick IHC and immunofluorescence assays (IF).

Scarcity Of Qualified Workers

Histology laboratories are vital to the accuracy, safety, and speed of sickness diagnosis. Histology is needed to understand illness causes and how therapies operate. Cancer rates increase the requirement for clinical histology services. 80% of cancer diagnostics involve histology. These facilities are understaffed.

According to inside lab 2020, only 3% of UK diagnostic labs had enough staff to perform diagnostic and regular tasks including reporting. Germany has the lowest proportion of pathologists to practising physicians in Europe, the US, and Canada. Germany's ratio is 1:200, while the US and Canada both have 1:70. PubMed 2020 as many histologists retire, few are entering the field. Histology labs are struggling to process more samples with fewer workers. This could limit cancer tissue diagnostics market growth.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Comparative View of Adjacent Cancer Tissue Diagnostics Market

Cancer Tissue Diagnostics Market:

Attributes	Cancer Tissue Diagnostics Market
CAGR (2022 to 2032)	6.6%
Market Value (2022)	US$ 5.3 Billion
Growth Factor	An increasing number of cases of cancer is expected to drive the cancer tissue diagnostics market.
Future Opportunities	Increased emphasis being placed on individualized medical cancer treatment which is opening new horizons in the cancer tissue diagnostics market.
Market Trends	Lack of available and skilled workers is expected to retrain the growth of the cancer tissue diagnostics market.

Molecular Diagnostics Market:

Attributes	Molecular Diagnostics Market
CAGR (2022 to 2032)	5.4%
Market Value (2022)	US$ 23.2 Billion
Growth Factor	Both increasing technological capabilities in molecular diagnostics and rising awareness of the importance of early disease diagnosis in developing countries are propelling the market forward.
Future Opportunities	Market leaders in molecular diagnostics can anticipate having expansion prospects in developing economies including India, China, South Korea, Brazil, Turkey, Russia, and South Africa.
Market Trends	A major barrier limiting the expansion of the molecular diagnostics business is inadequate reimbursements.

In vitro Diagnostics Market:

Attributes	In vitro Diagnostics Market
CAGR (2022 to 2032)	2.9%
Market Value (2022)	US$ 98.2 Billion
Growth Factor	The need is anticipated to be driven by the transition from centralised to point-of-care testing.
Future Opportunities	Potential growth possibilities for market players are anticipated to emerge from the development of disease-specific markers and diagnostics in the future years.
Market Trends	The in vitro diagnostics market is likely to slow down in the coming years due to the adverse reimbursement scenario.

The rising cancer cell rate has resulted in a surge in interest in oncology diagnostics. This has prompted government agencies, healthcare providers, and institutions to create facilities for effective illness diagnosis and treatment. Because of this, the cancer tissue diagnostics market is growing rapidly. Roche's uPath HER2 (4B5) and uPath HER2 Dual ISH digital pathology image analyzers are algorithms for precise patient diagnosis in breast cancer, and they were released in 2021. This is positively changing the cancer tissue diagnostics market outlook.

Country-Wise Analysis of the Cancer Tissue Diagnostics Market

United States	The United States has dominated the North American cancer tissue diagnostics market. Stakeholders in the U.S. business are expanding in response to an uptick in cancer diagnoses and improved diagnostic tools. As per the cancer tissue diagnostics market report, the average probability of a woman in the United States acquiring breast cancer in her lifetime is about 13%. An estimated 234,030 new instances of lung cancer were discovered in 2018, and there are already 541,000 Americans who have been diagnosed with lung cancer at some time in their lives. These findings show the vast potential for development and expansion in the U.S. cancer tissue diagnostics market.
Japan	Since the last decade, cancer tissue diagnostics in Japan has become an attractive market. The sophisticated diagnostics sector and the rising need to detect malignancies of the lung, breast, prostate, and elsewhere are driving this cancer tissue diagnostics market expansion in Japan. According to the "Global Cancer Data by Country" report by the World Cancer Research Fund, the most frequent malignancies in Japan are breast cancer, lung cancer, stomach cancer, colorectum cancer, and prostate cancer, with an age-standardized rate of 248.0 cases per 100,000 people. Due to the rising need for cancer tissue diagnostic solutions, businesses in the cancer tissue diagnostics market should expect increased profits in the future.
China	Supply companies in the cancer tissue diagnostics industry are taking notice of China because of its advanced medical and diagnostic sectors. The rising number of cancer cases in China is helping to fuel the cancer tissue diagnostics market expansion. About 4,285,033 new instances of cancer were identified in China in 20202, including 2,366,010 male and 1,919,023 female cases. According to the data presented, the crude and age-standardized death rates for men were 201.3 and 130.1 per 100,000, respectively. These projections indicate that China is likely to continue to be a focal point for the cancer tissue diagnostics industry.
Germany	The cancer tissue diagnostics market in Western Europe is currently led by Germany and is expected to be led by Germany for the foreseeable future. Germany's highly established manufacturing hubs and rising awareness of the need of early cancer detection test are driving the expansion. The World Cancer Research Fund reports that the age-adjusted rate of cancer in Germany is 313.1 cases per 100,000 people. This number includes cases of lung, breast, and prostate cancers. These numbers highlight expanding markets for German makers of diagnostic tools for cancer tissue.

Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Sign-Up

Competitive Landscape for the Cancer Tissue Diagnostics Market

Top companies in the cancer tissue diagnostics industry are paying more attention to the growing demand for their products in digital pathology. This is expected to prompt strategic partnerships in the global cancer tissue diagnostics market between technology providers and digital pathology platforms soon.

In July of 2020, for instance, Koninklijke Philips N.V., a Dutch multinational conglomerate corporation and one of the world's largest electronics companies with a focus on health technology, announced that it had partnered with Proscia Inc., a Philadelphia-based provider of digital pathology platform, to establish an open ecosystem for diagnostic laboratories to boost and scale their operations on the platform of digital pathologies.

Through this partnership, Philips' iSyntax image format is expected to be integrated with the Philips Pathology SDK software toolset and Proscia's suite of AI modules will be made available on the company's Concentriq digital pathology platform.

The Swiss pharmaceutical and diagnostics conglomerate F. Hoffmann-La Roche AG has announced the CE-IVD launch of its cutting-edge, fully automated digital pathology platform uPath PD-L1 (SP263) for non-small cell lung cancer research in June 2020. (NSCLC).

The firm stated that the decision was motivated by a desire to increase reliability and uniformity in diagnostic laboratories by implementing AI-powered image analysis capabilities.

Global Cancer Tissue Diagnostics Market Key Players

Abbott Laboratories
F.Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Ventana Medical Systems, Inc.
Bio Rad Laboratories Inc.
Enzo Life Sciences, Inc.
Abcam plc.
BioGenex
Cell Signalling Technology, Inc.
Agilent Technologies, Inc.
PerkinElmer Inc.
Bio SB
Cancer Genetics Inc.
Danaher Corporation
ROSETTA GENOMICS
Nanoprobes, Inc.
Creative-Biolabs
Enzo Life Sciences, Inc.
Sigma-Aldrich Co., LLC

3 AI Innovations Changing Cancer Diagnosis and Treatment

Cancer remains one of the world's deadliest diseases, despite significant progress in cancer treatment and detection over the previous several decades. The finest weapons doctors have against this disease are identification and treatment administered early on. However, difficulties, such as high false-positive rates and difficulty forecasting cancer treatment success, can impede the process.

Now, healthcare experts and medical researchers are discovering methods to use the latest advancements from outside of medicine - like artificial intelligence - to the diagnosis and treatment of cancer. Here are just three examples of such cutting-edge equipment.

Estimating the Likelihood of Successful Immunotherapy

Immunotherapy is a novel approach to cancer treatment that makes use of medications to stimulate the immune system to better combat cancer cells. When compared to conventional therapies like chemotherapy and radiation, this one often has less negative side effects and better success rates. Yet not every patient has the same experience, and the efficacy of immunotherapy cannot be predicted.

This could potentially alter with the introduction of a new artificial intelligence technology. Patients who are likely to benefit from immunotherapy could be selected using an algorithm in conjunction with routine CT scans. This would expedite their cancer treatment while also allowing doctors to treat other patients who are waiting for alternatives like chemotherapy.

Mass spectrometry imaging: Routine 3D tissue analysis is becoming a reality

The use of mass spectrometry for imaging purposes is a significant technological advance in spectral research. A 3D chemical map can be created by examining the spectra of individual molecules in tissue. This method has many potential applications, including the detection of hypoxic tumour sites, the characterization of spheroids, and the evaluation of alterations in the tumour microenvironment (TME). Recent technological advancements have made it possible to take these kinds of measurements at a high throughput, casting doubt on the feasibility of routine 3D tumour investigations.

Optimizing results from next-generation sequencing through careful tissue handling

Improvements in dependability and data management are largely responsible for the growth of next-generation sequencing in the therapeutic setting. The past decade has seen NGS facilitate the discovery of novel genomic variants and driving mutations, clarifying new targets for medication development. Researchers have also been able to pinpoint more accurate predictive and prognostic biomarkers for therapy thanks to NGS.

As part of its mission to promote improved diagnosis and cancer treatment decisions, Genomics England launched the 100,000 Genomes Initiative in 2012, making it the largest sequencing research project in the world. The research is also expected to improve techniques for 'genome-friendly' tissue processing.

Cancer Tissue Diagnostics Market by Segmentation

By Test Type:

Immunohistochemical (IHC) Test
- Breast Cancer
- Stomach (Gastric) Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
In Situ Hybridization (ISH) Test
- Breast cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Bladder Cancer
- Others

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa

Frequently Asked Questions

At What Rate the Cancer Tissue Diagnostics Market is Expected to Grow?

The cancer tissue diagnostics market is expected to grow at 6.6% CAGR over 2022-2032.

What is the Net Worth of the Global Cancer Tissue Diagnostics Market?

The cancer tissue diagnostics market is estimated to be around US$ 5.3 Billion in 2022.

What is the Projected Value of the Cancer Tissue Diagnostics Market?

The cancer tissue diagnostics market is anticipated to reach a valuation of US$ 10.04 Billion by 2032.

Which is the Rapidly Growing Region for the Cancer Tissue Diagnostics Market?

Cancer is one of several deadly diseases that have seen a dramatic increase in the United States, prompting a surge in cancer-related research and diagnostics across the continent of North America.

Table of Content

1. Executive Summary

2. Introduction

2.1. Definition

2.2. Taxonomy

3. Analysis Scenario

3.1. Size (US$ Mn) and Forecast

3.1.1. Market Size and Y-o-Y Growth

3.1.2. Absolute $ Opportunity

4. Analysis Scenario

4.1. Macro-economic Factors

4.2. Drivers

4.2.1. Supply Side

4.2.2. Demand Side

4.3. Restraints

4.4. Opportunity

4.5. Trends

4.6. Cancer Epidemiology

4.7. Regulatory and Reimbursement Scenario

4.8. Porter’s Analysis

5. Global Analysis and Forecast, By Test Type

5.1. Introduction

5.1.1. Basis Point Share (BPS) Analysis By Test Type

5.1.2. Y-o-Y Growth Projections By Test Type

5.2. Market Size (US$ Mn) Forecast By Test Type

5.2.1. Immunohistochemical (IHC) Test

5.2.1.1. Breast Cancer

5.2.1.2. Stomach (gastric) Cancer

5.2.1.3. Colorectal Cancer

5.2.1.4. Prostate Cancer

5.2.1.5. Others

5.2.2. In situ hybridization (ISH) Test

5.2.2.1. Breast Cancer

5.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

5.2.2.3. Bladder Cancer

5.2.2.4. Others

5.3. Market Attractiveness Analysis By Test Type

6. Global Analysis and Forecast, By Region

6.1. Introduction

6.1.1. Basis Point Share (BPS) Analysis By Region

6.1.2. Y-o-Y Growth Projections By Region

6.2. Market Size (US$ Mn) Forecast By Region

6.2.1. North America

6.2.2. Western Europe

6.2.3. Asia Pacific Excl. Japan (APEJ)

6.2.4. Japan

6.2.5. Latin America

6.2.6. Eastern Europe

6.2.7. Middle East and Africa (MEA)

6.3. Market Attractiveness Analysis By Region

7. North America Analysis and Forecast

7.1. Introduction

7.1.1. Basis Point Share (BPS) Analysis

7.1.2. Y-o-Y Growth Projections

7.2. Market Size (US$ Mn) Forecast By Test Type

7.2.1. Immunohistochemical (IHC) Test

7.2.1.1. Breast Cancer

7.2.1.2. Stomach (gastric) Cancer

7.2.1.3. Colorectal Cancer

7.2.1.4. Prostate Cancer

7.2.1.5. Others

7.2.2. In situ hybridization (ISH) Test

7.2.2.1. Breast Cancer

7.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

7.2.2.3. Bladder Cancer

7.2.2.4. Others

7.3. Market Value Forecast By Country, 2022-2032

7.3.1. United States

7.3.2. Canada

7.4. Market Attractiveness Analysis

7.4.1. By Test Type

7.4.2. By Country

8. Latin America Analysis and Forecast

8.1. Introduction

8.1.1. Basis Point Share (BPS) Analysis

8.1.2. Y-o-Y Growth Projections

8.2. Market Size (US$ Mn) Forecast By Test Type

8.2.1. Immunohistochemical (IHC) Test

8.2.1.1. Breast Cancer

8.2.1.2. Stomach (gastric) Cancer

8.2.1.3. Colorectal Cancer

8.2.1.4. Prostate Cancer

8.2.1.5. Others

8.2.2. In situ hybridization (ISH) Test

8.2.2.1. Breast Cancer

8.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

8.2.2.3. Bladder Cancer

8.2.2.4. Others

8.3. Market Value Forecast By Country, 2022-2032

8.3.1. Brazil

8.3.2. Mexico

8.3.3. Rest of Latin America

8.4. Market Attractiveness Analysis

8.4.1. By Test Type

8.4.2. By Country

9. Western Europe Analysis and Forecast

9.1. Introduction

9.1.1. Basis Point Share (BPS) Analysis

9.1.2. Y-o-Y Growth Projections

9.2. Market Size (US$ Mn) Forecast By Test Type

9.2.1. Immunohistochemical (IHC) Test

9.2.1.1. Breast Cancer

9.2.1.2. Stomach (gastric) Cancer

9.2.1.3. Colorectal Cancer

9.2.1.4. Prostate Cancer

9.2.1.5. Others

9.2.2. In situ hybridization (ISH) Test

9.2.2.1. Breast Cancer

9.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

9.2.2.3. Bladder Cancer

9.2.2.4. Others

9.3. Market Value Forecast By Country, 2022-2032

9.3.1. UK

9.3.2. France

9.3.3. Germany

9.3.4. Spain

9.3.5. Italy

9.3.6. Rest of Western Europe

9.4. Market Attractiveness Analysis

9.4.1. By Test Type

9.4.2. By Country

10. Eastern Europe Analysis and Forecast

10.1. Introduction

10.1.1. Basis Point Share (BPS) Analysis

10.1.2. Y-o-Y Growth Projections

10.2. Market Size (US$ Mn) Forecast By Test Type

10.2.1. Immunohistochemical (IHC) Test

10.2.1.1. Breast Cancer

10.2.1.2. Stomach (gastric) Cancer

10.2.1.3. Colorectal Cancer

10.2.1.4. Prostate Cancer

10.2.1.5. Others

10.2.2. In situ hybridization (ISH) Test

10.2.2.1. Breast Cancer

10.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

10.2.2.3. Bladder Cancer

10.2.2.4. Others

10.3. Market Value Forecast By Country, 2022-2032

10.3.1. Russia

10.3.2. Poland

10.3.3. Rest of Eastern Europe

10.4. Market Attractiveness Analysis

10.4.1. By Test Type

10.4.2. By Country

11. Asia Pacific Excl. Japan (APEJ) Analysis and Forecast

11.1. Introduction

11.1.1. Basis Point Share (BPS) Analysis

11.1.2. Y-o-Y Growth Projections

11.2. Market Size (US$ Mn) Forecast By Test Type

11.2.1. Immunohistochemical (IHC) Test

11.2.1.1. Breast Cancer

11.2.1.2. Stomach (gastric) Cancer

11.2.1.3. Colorectal Cancer

11.2.1.4. Prostate Cancer

11.2.1.5. Others

11.2.2. In situ hybridization (ISH) Test

11.2.2.1. Breast Cancer

11.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

11.2.2.3. Bladder Cancer

11.2.2.4. Others

11.3. Market Value Forecast By Country, 2022-2032

11.3.1. China

11.3.2. Australia

11.3.3. India

11.3.4. ASEAN

11.3.5. Rest of APEJ

11.4. Market Attractiveness Analysis

11.4.1. By Test Type

11.4.2. By Country

12. Japan Analysis and Forecast

12.1. Introduction

12.1.1. Basis Point Share (BPS) Analysis

12.1.2. Y-o-Y Growth Projections

12.2. Market Size (US$ Mn) Forecast By Test Type

12.2.1. Immunohistochemical (IHC) Test

12.2.1.1. Breast Cancer

12.2.1.2. Stomach (gastric) Cancer

12.2.1.3. Colorectal Cancer

12.2.1.4. Prostate Cancer

12.2.1.5. Others

12.2.2. In situ hybridization (ISH) Test

12.2.2.1. Breast Cancer

12.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

12.2.2.3. Bladder Cancer

12.2.2.4. Others

12.3. Market Attractiveness Analysis

12.3.1. By Test Type

13. MEA Analysis and Forecast

13.1. Introduction

13.1.1. Basis Point Share (BPS) Analysis

13.1.2. Y-o-Y Growth Projections

13.2. Market Size (US$ Mn) Forecast By Test Type

13.2.1. Immunohistochemical (IHC) Test

13.2.1.1. Breast Cancer

13.2.1.2. Stomach (gastric) Cancer

13.2.1.3. Colorectal Cancer

13.2.1.4. Prostate Cancer

13.2.1.5. Others

13.2.2. In situ hybridization (ISH) Test

13.2.2.1. Breast Cancer

13.2.2.2. Non-Small Cell Lung Cancer (NSCLC)

13.2.2.3. Bladder Cancer

13.2.2.4. Others

13.3. Market Value Forecast By Country, 2022-2032

13.3.1. GCC Countries

13.3.2. South Africa

13.3.3. Rest of MEA

13.4. Market Attractiveness Analysis

13.4.1. By Test Type

13.4.2. By Country

14. Competition Landscape

14.1. Competition Dashboard

14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

14.2.1. Abbott Laboratories

14.2.1.1. Overview

14.2.1.2. Financials

14.2.1.3. Strategy

14.2.1.4. Recent Developments

14.2.2. F. Hoffmann-La Roche Ltd.

14.2.2.1. Overview

14.2.2.2. Financials

14.2.2.3. Strategy

14.2.2.4. Recent Developments

14.2.3. Thermo Fisher Scientific Inc.

14.2.3.1. Overview

14.2.3.2. Financials

14.2.3.3. Strategy

14.2.3.4. Recent Developments

14.2.4. Ventana Medical Systems, Inc

14.2.4.1. Overview

14.2.4.2. Financials

14.2.4.3. Strategy

14.2.4.4. Recent Developments

14.2.5. Bio Rad Laboratories Inc.

14.2.5.1. Overview

14.2.5.2. Financials

14.2.5.3. Strategy

14.2.5.4. Recent Developments

14.2.6. Enzo Life Sciences, Inc.

14.2.6.1. Overview

14.2.6.2. Financials

14.2.6.3. Strategy

14.2.6.4. Recent Developments

14.2.7. Abcam plc.

14.2.7.1. Overview

14.2.7.2. Financials

14.2.7.3. Strategy

14.2.7.4. Recent Developments

14.2.8. BioGenex

14.2.8.1. Overview

14.2.8.2. Financials

14.2.8.3. Strategy

14.2.8.4. Recent Developments

14.2.9. Cell Signaling Technology, Inc.

14.2.9.1. Overview

14.2.9.2. Financials

14.2.9.3. Strategy

14.2.9.4. Recent Developments

14.2.10. Agilent Technologies, Inc.

14.2.10.1. Overview

14.2.10.2. Financials

14.2.10.3. Strategy

14.2.10.4. Recent Developments

14.2.11. PerkinElmer Inc.

14.2.11.1. Overview

14.2.11.2. Financials

14.2.11.3. Strategy

14.2.11.4. Recent Developments

14.2.12. Bio SB

14.2.12.1. Overview

14.2.12.2. Financials

14.2.12.3. Strategy

14.2.12.4. Recent Developments

14.2.13. Cancer Genetics Inc.

14.2.13.1. Overview

14.2.13.2. Financials

14.2.13.3. Strategy

14.2.13.4. Recent Developments

14.2.14. Danaher Corporation

14.2.14.1. Overview

14.2.14.2. Financials

14.2.14.3. Strategy

14.2.14.4. Recent Developments

14.2.15. ROSETTA GENOMICS

14.2.15.1. Overview

14.2.15.2. Financials

14.2.15.3. Strategy

14.2.15.4. Recent Developments

14.2.16. Nanoprobes, Inc.,

14.2.16.1. Overview

14.2.16.2. Financials

14.2.16.3. Strategy

14.2.16.4. Recent Developments

14.2.17. Creative-Biolabs

14.2.17.1. Overview

14.2.17.2. Financials

14.2.17.3. Strategy

14.2.17.4. Recent Developments

14.2.18. Enzo Life Sciences, Inc

14.2.18.1. Overview

14.2.18.2. Financials

14.2.18.3. Strategy

14.2.18.4. Recent Developments

14.2.19. Sigma-Aldrich Co. LLC

14.2.19.1. Overview

14.2.19.2. Financials

14.2.19.3. Strategy

14.2.19.4. Recent Developments

15. Assumptions and Acronyms Used

16. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

Customize Now

List of Tables

Table 1: Global Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 2: Global Market Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

Table 3: North America Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 4: North America Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 5: Latin America Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 6: Latin America Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 7: Western Europe Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 8: Western Europe Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 9: Eastern Europe Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 10: Eastern Europe Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 11: APEJ Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 12: APEJ Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Regional market revenue growth for both tests is expected to remain sTable over the forecast period, given rising demand

Table 13: Japan Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Table 14: MEA Market Value (US$ Mn) Analysis and Forecast By Country, 2022-2032

Table 15: MEA Market Value (US$ Mn) Analysis and Forecast By Test Type, 2022-2032

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2022-2032

Figure 2: Global Market Absolute $ Opportunity, 2022-2032

Figure 3: Global Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 4: Global Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 5: Global Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 6: Global Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 7: Global Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 8: Global Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 9: Global Market Share Analysis (%) By Region, 2022 & 2032

Figure 10: Global Market Y-o-Y Growth (%) By Region, 2022-2032

Figure 11: North America Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 12: Latin America Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 13: Western Europe Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 14: Eastern Europe Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 15: APEJ Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 16: Japan Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 17: MEA Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 18: Global Market Attractiveness Analysis By Region, 2022-2032

Figure 19: North America Market Share Analysis (%) By Country, 2022, 2032

Figure 20: North America Market Y-o-Y Growth (%) By Country, 2022-2032

Figure 21: North America Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 22: North America Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 23: North America Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 24: North America Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 25: U.S. Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 26: Canada Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 27: North America Market Attractiveness Analysis By Country, 2022-2032

Figure 28: North America Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 29: North America Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 30: Latin America Market Share Analysis (%) By Country, 2022 & 2032

Figure 31: Latin America Market Y-o-Y Growth (%) By Country, 2022-2032

Figure 32: Latin America Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 33: Latin America Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 34: Latin America Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 35: Latin America Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 36: Brazil Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 37: Mexico Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 38: Rest of Latin America Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 39: Latin America Market Attractiveness Analysis By Test Type, 2022-2032

Figure 40: Latin America Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 41: Latin America Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 42: Western Europe Market Share Analysis (%) By Country, 2022 & 2032

Figure 43: Western Europe Market

Figure 44: Western Europe Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 45: Western Europe Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 46: Western Europe Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 47: Western Europe Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 48: Germany Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 49: Italy Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 50: France Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 51: U.K. Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 52: Spain Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 53: Rest Of Western Europe Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 54: Western Europe Market Attractiveness Analysis By Test Type, 2022-2032

Figure 55: Western Europe Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 56: Western Europe Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 57: Eastern Europe Market Share Analysis (%) By Country, 2022 & 2032

Figure 58: Eastern Europe Market Y-o-Y Growth (%) By Country, 2022-2032

Figure 59: Eastern Europe Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 60: Eastern Europe Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 61: Eastern Europe Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 62: Eastern Europe Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 63: Poland Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 64: Russia Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 65: Rest of Eastern Europe Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 66: Eastern Europe Market Attractiveness Analysis By Test Type, 2022-2032

Figure 67: Eastern Europe Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 68: Eastern Europe Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 69: APEJ Market Share Analysis (%) By Country, 2022 & 2032

Figure 70: APEJ Market Y-o-Y Growth (%) By Country, 2022-2032

Figure 71: APEJ Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 72: APEJ Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 73: APEJ Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 74: APEJ Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 75: China Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 76: India Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 77: ASEAN Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 78: Australia Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 79: Rest of APEJ Europe Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 80: APEJ Market Attractiveness Analysis By Test Type, 2022-2032

Figure 81: APEJ Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 82: APEJ Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 83: Japan Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 84: Japan Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 85: Japan Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 86: Japan Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 87: Japan Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 88: Japan Market Attractiveness Analysis By ISH Test, 2022-2032

Figure 89: MEA Market Share Analysis (%) By Country, 2022, 2032

Figure 90: MEA Market Y-o-Y Growth (%) By Country, 2022-2032

Figure 91: MEA Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2022 & 2032

Figure 92: Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2022-2032

Figure 93: MEA Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2022 & 2032

Figure 94: MEA Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2022-2032

Figure 95: GCC Countries Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 96: South Africa Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 97: Rest of MEA Europe Market Absolute $ Opportunity (US$ Mn), 2022-2032

Figure 98: MEA Market Attractiveness Analysis By Test Type, 2022-2032

Figure 99: MEA Market Attractiveness Analysis By IHC Test, 2022-2032

Figure 100: MEA Market Attractiveness Analysis By ISH Test, 2022-2032

September 2022
REP-GB-4191
324 pages
Healthcare

Book Now

CUSTOMIZE THIS RESEARCH

Which are the positive and negative factors impacting the Cancer Tissue Diagnostics Market
How can you develop stable and lucrative revenue streams?
What will be your strategy to make top customers shift towards your brand?
Which significant steps can you take to stay ahead of competitors?
Get a complete personalized report with a scorecard of target partners

Customize Now